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Abstract: Induced pluripotent stem cells (iPSCs)-based two-dimensional (2D) protocols have offered
invaluable insights into the pathophysiology of neurological diseases. However, these systems
are unable to reproduce complex cytoarchitectural features, cell-cell and tissue-tissue interactions
like their in vivo counterpart. Three-dimensional (3D)-based culture protocols, though in their
infancy, have offered new insights into modeling human diseases. Human neural organoids try to
recapitulate the cellular diversity of complex tissues and can be generated from iPSCs to model the
pathophysiology of a wide spectrum of pathologies. The engraftment of iPSCs into mice models
and the improvement of differentiation protocols towards 3D cultures has enabled the generation of
more complex multicellular systems. Consequently, models of neuropsychiatric disorders, infectious
diseases, brain cancer and cerebral hypoxic injury can now be investigated from new perspectives.
In this review, we consider the advancements made in modeling neuropsychiatric and neurological
diseases with iPSC-derived organoids and their potential use to develop new drugs.
Keywords: brain organoids; neurological disorders; iPSCs; drug discovery; disease modeling;
neural chimera
1. Introduction
Recent technological advances achieved in stem cell research have provided unprecedented means
to study the nervous system, both in vitro and in vivo. The enthusiasm for stem cell-based technologies
rose with the development of embryonic stem cells (ESCs) cultures, followed by human-induced
pluripotent stem cells (iPSCs) and, lately, by ESCs- and iPSCs-derived three-dimensional (3D)
culture systems.
Human ESC lines were first isolated in 1998 [1] and differentiation protocols towards multiple
tissues were soon designed, aiming to eventually develop allogeneic cell-based therapies to several
degenerative diseases. As for neural disease modeling, ESCs were successfully differentiated to neural
precursors [2] and many neuronal subtypes, e.g., dopaminergic neurons [3] and motor neurons [4], as
well as astrocytes [5], oligodendrocytes [6] and microglia [7]. However, ESCs advantages were offset by
the need of genetic manipulation to introduce disease-relevant mutations and their limited supply [8].
Human iPSCs reprogrammed from patients’ somatic cells such as fibroblasts and blood cells [9–11]
have given new stimuli in many fields of neurobiology: they provided researchers with patient-derived
human stem cells offering a more scalable supply for culturing systems and the theoretical possibility
of personalized autologous therapies for a wide spectrum of diseases [12]. Moreover, iPSCs can
be differentiated into cells able to recapitulate the hallmarks of pathological cells and tissues to
develop disease models and test new potential therapies [13]. Many neural diseases have already been
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modeled using iPSCs and their pathological features thoroughly described: hyperexcitability, altered
axonal transport and increased apoptosis in spinal muscular atrophy (SMA) neurons [14,15]; elevated
lysosomal activity and higher response to glutamate in iPSC-derived neurons from Huntington disease
patients [16–18]; decreased dendritic length and altered calcium signaling in neurons derived from
patients with Timothy syndrome (TS) [19]; altered mitochondrial activity, abnormal mRNA expression
and lithium-responsive hyperexcitability from patients diagnosed with bipolar disorder [20,21].
These phenotypes are reproducible, scalable and disease-relevant, offering an important insight into
some intrinsic pathological mechanisms at a cellular level.
Although these systems have increased the understanding of different diseases, human pathologies
arise in the context of complex interactions at a cell-, tissue-, organ- and host-pathogen level. Therefore,
new culture systems are being developed to more closely recapitulate dysfunctions at organ- and
tissue-level, enabling new approaches to disease modeling and compound screening (Figure 1). Recently,
3D culture methods have been implemented, primarily leading to the generation of organoids [22–24],
a complex self-organizing 3D aggregate of different cell types derived from ESCs or iPSCs capable of
going through the differentiation and morphogenesis pathways down to recapitulate core features of
full-grown tissues. The first in vitro attempt to grow 3D neural tissue dates back to 2008, when the
method of serum-free floating culture of embryoid body-like aggregates with quick reaggregation
(SFEBq) was tuned [25]. In 2013, Lancaster et al. discovered that embryoid bodies embedded in Matrigel,
in absence of small molecules prompting specific regional patterning, gave rise to neuroepithelial buds
subsequently maturing in different brain regions [22]. In recent years, new data have been provided
regarding organoid generation and patterning [22,26,27]. Indeed, several groups have developed
multiple differentiation protocols to generate varying central nervous system (CNS) regions including
ventral forebrain [28], midbrain [29], hippocampus [30], hypothalamus [29], dorsal cortex [31] and
spinal cord [32].
In addition, different neural organoid-based researches have tried to model neurological diseases
and neurodegeneration [33]. Although it is unclear how much insight can be gained from neural
organoids to model neurodegenerative diseases, some studies suggest that they may be relevant in
recapitulating some late-onset phenotypes, such as Alzheimer disease (AD). The main neuropathological
features of AD are neurofibrillary tangles composed of hyperphosphorylated tau protein and the
extracellular accumulation of amyloid-β peptides [34]. 2D cultures may not be suitable to model the
complex extracellular compartment required to reproduce the extracellular amyloid deposition, making
3D cultures potentially promising alternatives. For example, a research investigating familial AD
(fAD) mutations of β-amyloid precursor protein and presenilin 1 has shown extracellular deposition of
amyloid-β in a human stem cell-based 3D culture system [35]. Moreover, neural cells differentiated
within this 3D culture system present both filamentous and phosphorylated tau protein aggregates.
Consistently with these findings, also neural organoids from murine iPSCs display high levels of ptau
and extracellular β-amyloid [36]. Raja et al. has obtained similar results from fAD patient-derived
neural organoids, exhibiting AD-like phenotype such as hyperphosphorylated tau aggregation,
endosome abnormalities and extracellular amyloid accumulation [37]. These results are important
because they are difficult to reproduce in mice models of fAD [33,38] and suggest that neural organoids
are a suitable model to recapitulate some aspects of fAD-related phenotype.
In parallel to disease modeling, the development of xenotransplantation, that is the transplantation
of cells from a species to different species, is expanding the possibility of generating even more complex
iPSC-derived biological systems, the so-called chimaeras. Chimeric models allow one to study
iPSCs-derived cells and organoids integrated within the CNS in a more physiological environment,
where they are perfused by the host vasculature and interact with microglia and surrounding neural
networks [39,40]. Consequently, engrafted organoids could more faithfully recapitulate differentiation
as a result of the exposure to morphogenetic cues and to sensory signals conveyed through the host
neural system.
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Figure 1. Drug discovery based on induced pluripotent stem cells (iPSCs) and iPSC-derived systems.
The improvements made in iPSCs culturing and differentiation methods have increased the efficiency
and the quality of iPSCs lines. In addition, the use of gene correction technologies such as CRISPR-Cas9
and specific small molecules has enabled the generation of patient isogenic lines and terminally
differentiated cells, reducing background genetic variability and broadening the spectrum of cells
available for drug screening. Currently, some candidate therapies discovered with iPSC-based platforms
and chimeric models ar being t sted in human clinical trials. In parallel, optimizati n in the efficiency
and scalability of clinical-grade cells h s led to iPSC-derived neural c lls transplan ation i humans.
In this review, we consider the advancements made in modeling neuropsychiatric and neurological
diseases with iPSC-derived organoids and their potential use to develop new drugs. The engraftment
of iPSCs into mice models and the improvement of differentiation protocols towards 3D cultures
has enabled the generation of more complex multicellular systems. As a consequence, models of
neuropsychiatric disorders, infectious diseases, brain cancer and cerebral hypoxic injury can now be
investigated from new perspectives (Table 1).
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Table 1. Selected studies investigating neurological and neuropsychiatric disorders using human iPSC-derived 3D organoids.
Disease Organoid Type Days ofDifferentiation Phenotype and Rescue Unique Experimental Feature Protocol
Timothy Syndrome [41] Ventral and dorsalforebrain, assembloids 4 weeks
GABAergic interneuron abnormalities: altered saltation
frequency and shorter saltation length; phenotype rescue by
pharmacological modulation of l-type calcium channels
Forebrain assembloids with labelling of specific cell type
(Dlxi1/2b::eGFP) [42]
Autism Spectrum Disorder [43] Dorsal forebrain 6 weeks
Transcriptome dysregulation: FOXG1 upregulation; increased
production of NPCs and GABAergic neurons; rescue by shRNA
attenuation of FOXG1 expression
Lentiviral-mediated expression of shRNA-FOXG1 [23]
Miller-Dieker Syndrome [44] Forebrain 4 weeks
Smaller organoids with reduced neuroepithelial loops,
impaired vRG divisions, disrupted cortical niche; rescue by
gene re-expression or β-catenin activation
Doxycycline-inducible overexpression of LIS1 gene [45,46]
Autosomal recessive primary
microcephaly [22] Undirected ~3 weeks
Altered vRG morphology and orientation, smaller organoids;
rescue by shRNA for CDK5RAP2
Electroporation-mediated overexpression of CDK5RAP2 and
shRNA-CDK5RAP2 [22]
Hypoxic injury [47] Forebrain ~11 weeks
Disruption of intermediate progenitors in SVZ; impaired UPR
pathway activation and premature neuronal differentiation;
rescue by stress response inhibitor (ISRIB)
Gas control chamber and needle-type fiber-optic microsensor to
reproduce and monitor low oxygen exposure [42]
Zika virus infection (ZIKV) [29] Forebrain ~3 months Smaller organoids with reduced thickness and increasedventricular lumen, ZIKV-induced cell apoptosis
ZIKV strains: MR766 and FSS13025 (99% amino acid sequence
homology to Brazilian ZIKV) [29]
Cytomegalovirus infection (CMV) [48] Undirected 8 weeks Reduced cell proliferation, necrosis, vacuolar and cysticdegeneration; impaired cortical lamination Organoid differentiation from CMV-infected hiPSCs [46]
Creutzfeld-jakob disease (CJD) [49] Undirected 5 months Slow metabolism, protease-resistant PrP deposition, acquiredprion seeding activity, increased astrocyte activation
Organoids inoculation with human brain homogenates from
sporadic CJD subtypes [46]
Brain tumors [50] Forebrain ~4 months
Glioma-like with poor glial differentiation, high cell
proliferation, disorganized architecture and downregulation of
PI3K-AKT, RAS pathways; CNS-PTEN-like with WNT, TGFβ,
and TP53 upregulation; tumor invasiveness upon in vivo
transplantation; partial rescue in glioma by EGFR-inhibitors
Electroporation-mediated plasmid nucleofection with
overexpression of MYC/inhibition of tumor suppressor genes [22]
Cells 2019, 8, 1438 5 of 21
2. Modeling Neuropsychiatric and Neurodevelopmental Disorders
Despite progress in neuroscience, the biological basis of neuropsychiatric disorders is still
elusive [51]. Two of the main challenges to be faced are the complexity of the human brain, containing
different types of specialized cells and connections, and the heterogeneous factors playing a causative
role in neuropsychiatric diseases. The latter includes an intricate interplay of environmental, genetic and
psychosocial factors, difficult to reproduce in animal models or in vitro [52]. The lack of neurobiological
markers represents another limitation, since many disorders are labeled into clinical categories by
behaviors and self-reported disturbances [53]. Moreover, neuropsychiatric disorders present obstacles
both in treatment and drug development in reliable models [54].
Recent techniques offer the opportunity to study nervous system diseases from new viewpoints.
For example, genomic analysis has contributed to the definition of copy number and genetic variants
as risk factors for increased susceptibility to neuropsychiatric conditions [55]. In addition, clustered
regularly interspersed short palindromic repeats (CRISPR)-Cas9, a revolutionary genome engineering
tool, has led to efficient and precise genome changes for the study of gene-function correlations both
in vitro and in animal models [56]. In parallel, iPSCs can be derived from selected patients with
increased disease susceptibility by carrying accumulation of common variants with small effect or
rare ones of large effect, such as in schizophrenia (SCZ). Different studies on 2D and 3D cultures
have provided important advancements in modelling SCZ [57]. For example, iPSC-derived forebrain
organoids from SCZ patients show disrupted neocorticogenesis [58]. Particularly, they exhibit (i)
enhanced proliferation of neural precursor cells (NPCs), (ii) reduced expression of reelin, a protein
regulating migration towards the cortex, (iii) decreased cortical neuron development in favor of a
subcortical pattern and (iv) morphologically altered interneurons, which support the connection
between cortical columns. These findings are consistent with 2D-based studies showing impaired
migration, proliferation and differentiation of iPSC-derived NPCs and neurons from SCZ patients [57].
Although environmental influences remain to be elucidated, examples that 3D-culture protocols can
be integrated with gene editing technologies and refined to model specific aspects of neuropsychiatric
diseases include Timothy syndrome, autism spectrum disorders (ASDs) and tuberous sclerosis
complex (TSC)
2.1. Timothy Syndrome
Brain organoids can model monogenic causes of ASD enabling the investigation of gene-phenotype
relationship during human cortical maturation.
Recently, Birey et al. have modelled Timothy syndrome, a genetic disease caused by a mutation in
the l-type calcium channel CACNA1C associated with epilepsy and ASD, using iPSCs-derived ventral
and dorsal forebrain organoids [41]., Cortical maturation involves the specification and functional
interplay between glutamatergic neurons in dorsal forebrain (pallium) and gamma-hydroxybutyrate
(GABA)-releasing interneurons in ventral forebrain (subpallium) [59]. The differentiation towards a
ventral or dorsal forebrain fate has been assessed using immunostaining and single-cell transcriptional
profiling. Particularly, dorsal forebrain organoids show increased expression of intermediate
progenitors (TBR2 and HES6), dorsal progenitors (LHX2, PAX6, GLAST1) as well as glutamatergic
neurons (VGLUT1+) exhibiting cortical layer markers (TBR1 and CTIP2). Instead, ventral forebrain
organoids present typical subpallial markers (GABA, GAD67, somatostatin, calretinin and calbindin),
known markers identifying GABAergic interneurons [41].
After differentiation, interneurons migrate during fetal development from the ganglionic eminence
to the developing neocortex undergoing maturation and integration into cortical circuits [60]; early
circuit alterations can lead to neuropsychiatric manifestations including ASD and epilepsy. Assembling
ventral and dorsal forebrain organoids into so called “assembloids” enables to model the integration
of GABA interneurons into functional microcircuits and their saltatory migration into the cerebral
cortex during brain development [41,61]. Saltatory migration is a cyclical movement of an extension
of the neuronal leading process in one direction followed by a transient swelling of the soma and
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nuclear translocation (nucleokinesis) [62]. These steps are repeated generating the typical saltatory
pattern of migrating neurons. When assembled with dorsal forebrain organoids, TS ventral forebrain
organoids labeled with a Dlxi1/2b-GFP+ reporter of GABA interneurons show a disrupted saltatory
pattern, culminating in delayed neuronal migration on live imaging. Blocking l-type calcium channel
with nimodipine or roscovitine restores the phenotypes in diseased assembloids [41] (Figure 2).
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Figure 2. iPSC-derived neural organoids in disease modeling. The figure shows examples of different
diseases modelled using neural organoids. Neuropsychiatric disorders, uch as Ti othy syndrome,
can be modell d with dorsal and ventral forebrain organoids generating assembloids, which exhibit
alterations in neuronal saltatory migration that can be corrected with the l-type channel blocker
nimodipine (upper left corner). Zika virus- ost interaction in human neural organoids leads to
morphological and cytoarchitectural abnormalities (upper right corner). Neural organoids can be
co-cultured with cancer stem cells (CSCs) to model human brain tumors and test therapeutic approaches
such as radiotherapy (lower left corner). Cortical organoids exposed to low oxygen concentration in
gas chambers recapitulate some cytoarchitectural abnormalities present in fetal hypoxic injury (lower
right corner).
In the same study, Birey et al. have also investigated the functional properties of TS assembloids
using calcium imaging and whole-cell patch clamping. Similarly to results in hiPSC-derived TS
neural cells [19], neurons from TS assembloids exhibit increased residual calcium in response to
depolarization. Moreover, TS assembloids present functional synapsis, showing integration of ventral
and forebrain organoids into neural networks responsive to electrical stimuli. These results are
important because indicate the possibility of generating active and synaptically connected human
microcircuits in 3D cultures.
This research shows how neural organoids can be differentiated into more specialized brain
regions modeling specific neurobiological processes. Particularly, by modifying culture conditions
of human organoids, several protocols have been used to direct differentiation towards the cerebral
cortex [35], the ventral and dorsal forebrain [41], the cerebellum [63] the midbrain [64] and the basal
ganglia [65]. These directed brain organoids can be assembled in multicellular structures reproducing
cell-cell interactions and neural circuitry that can be useful to model diseases where cell migration and
neural circuitry disruption seem to play an important role such as in neurodevelopmental disorders.
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2.2. Autism Spectrum Disorders
Autism spectrum disorders (ASD) refer to a group of neurodevelopmental disturbances defined
by difficulty with communication with other people, restriction in interests and repetitive behaviors,
affecting the patient’s ability to function properly in different areas of life. Genetic hereditability is a
risk factor for ASD and several copy number variants and different mutations have been associated
with subtypes of ASDs with varying penetrance and variable expressivity [49,61].
Almost 90% of all ASD cases are considered idiopathic and few studies have tried to model
them [66]. In a study by Mariani et al., iPSC-derived dorsal telencephalic organoids have been generated
from ASD patients with macrocephaly and no ASD-related mutation as shown by whole genome
analysis [36]. ASD organoids have been characterized using immunochemistry, electrophysiological
and transcriptomic analysis. Transcriptomes of ASD organoids have been compared both with
controls and BrainSpan, a dataset of postmortem human brain transcriptomes from embryonic age to
adulthood [67]. ASD organoids show dysregulated transcripts implicated in cell proliferation, neuronal
differentiation, synaptic transmission and reflect the transcriptome of the human dorsal telencephalon
(cerebral cortex and hippocampus) during early fetal development (9 weeks post-conception) [43].
Moreover, immunohistochemistry techniques reveal an increased number of progenitors, GABAergic
neurons and a transient increase in size during maturation. In parallel, as shown using whole-cell
patch-clamp recordings, ASD neural organoids present functional synaptic connections. Particularly,
most neurons in the organoid fire only a single action potential, but some show multiple spikes and
spontaneous synaptic currents. In addition, they present an enhanced expression of GABAergic
phenotypes electrophysiologically, consistent with an increased presence of a specific sodium channel
isoform in ASD organoids [43]. Differential gene expression analysis on ASD organoids shows that
one of the most upregulated genes is FOXG1, an important regulator of forebrain differentiation linked
to ASD-like neurodevelopmental syndromes [62,63]. The attenuation of FOXG1 expression by short
hairpin RNA reverts the abnormal high presence of GABAergic neurons [36]. This study highlights
how human iPSC-derived cortical organoids recapitulating first trimester brain development can be
useful in assessing the formation of functional synaptic connectivity as well as the altered dynamics of
brain growth in idiopathic ASD presenting with macrocephaly.
In another study, telencephalic organoids derived from iPSCs carrying a CRISPR-cas9-induced
heterozygote mutation of CDH8 (an ASD-related chromatin remodeling factor) have been used to
model a form of non-idiopathic ASD [68]. Derived organoids exhibit increased expression of genes
involved in differentiation of GABAergic neurons, consistent with the results obtained in idiopathic
ASD [43], suggesting the presence of common molecular pathways in different clinical conditions
caused by apparently unrelated genetic background.
These observations illustrate how 3D cultures coupled with gene editing techniques may be
exploited to investigate the molecular basis of genetically heterogeneous disorders such as ASDs.
2.3. Tuberous Sclerosis Complex
Tuberous sclerosis complex is an autosomal dominant, systemic disease characterized by epilepsy,
ASD, delayed intellectual development and psychiatric manifestations associated with mutations in
TSC1 and TSC2 genes [69]. TSC1 and TSC2 mutations lead to an increased activation of mammalian
target of rapamycin (mTOR) complex, a serine/threonine kinase involved in cell proliferation and
metabolism in response to growth factors and nutrients [70]. Cortical tubers, which are focal areas of
disorganized and dysplastic neurons, glia and giant cells in cortical layers, are the hallmark of TSC [71].
Recently, cortical organoids have been generated to model tuberous sclerosis by introducing
TSC1 and TSC2 mutations with CRISPR-cas9 editing in hESCs and from patient-derived iPSCs [72].
Organoids carrying heterozygous mutations of TSC1 and TSC2 show no abnormalities in neuronal or
glial differentiation, while homozygous knockout organoids display an altered balance of neurons and
glia with reduced expression of neuronal markers and hypertrophy of glial lineages. Both neurons and
glial cells within brain organoids are highly dysmorphic and increased in size over time, similarly to
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observations in cortical tubers from patients’ samples [71]. Organoids obtained from patient-derived
iPSCs with TSC2 heterozygous mutation and edited with a mutated TSC2 conditional allele prove that
biallelic inactivation of TSC2 is needed to reproduce the phenotype at a cellular level [72]. These results
are in line with loss of TSC1 and TSC2 heterozygosity leading to dysplastic cell formation in cortical
tubers [73]. Rapamycin and its derivative everolimus (also called rapalogues) can be used to treat both
epilepsy and subependymal giant cell astrocytomas, glioneural brain tumors occurring in 20% of TSC
patients [74]. However, if the treatment is stopped the tumor can regrowth [73]. Rapamycin in TSC
organoids prevents mTOR hyperactivation in early-stage TSC2 homozygous knockout cultures and
rescue cellular hypertrophy, but later treatment does not, suggesting a critical therapeutic window
for mTOR to regulate cell differentiation in brain development. In addition, removal of rapamycin
in early-treated organoids is associated with mTOR hyperactivity, suggesting the potential need for
chronic use of rapalogues to treat TSC [72]. Thus, neural organoids permit to investigate the effects
of currently available drugs on a multicellular scale and can faithfully recapitulate cytoarchitectural
features and genetic expressivity of complex neuropsychiatric disorders such as TSC.
3. Organoid Models of Neural Hypoxic Injury
The technological advances in neonatal care have increased the survival rates of extremely
premature infants, defined as born before post-conception week 28. These critical developmental stages
coincide with the formation of the human cerebral cortex and can be disrupted by hypoxic injuries.
Hypoxic-derived encephalopathy (HE) presents with gray- and white-matter abnormalities correlating
both with the cognitive outcome and behavioral disorders. Perinatal hypoxia, defined as a decreased
partial pressure of oxygen (PO2) below 40 mmHg, is considered to be the main cause of HE, inducing
molecular changes on susceptible cortical cells that still remain unknown [75]. Some challenges in
solving this issue are related to the difficulty in directly investigating the pre-birth human brain and
recapitulating its maturation in animal models.
In recent research, brain-region-specific organoids mimicking the developing human brain have
been differentiated to human cortical spheroids transcriptionally resembling the midgestation brain [47]
to model the effect of oxygen reduction on corticogenesis in premature newborns [47]. Specific organoid
subregions such as the subventricular zone (SVZ), a highly proliferative area adjacent to the ventricular
zone, where neurogenesis progresses until late gestation phase, are more susceptible to damage induced
by oxygen deprivation. Particularly, low level of PO2 affect a specific neuronal subpopulation, TBR2+
intermediate progenitors, active cells residing the SVZ that are involved in increasing the number of
cells in the neocortex (Figure 2). Interestingly, PAX6+ radial glia cells residing the ventricular zone,
an organoid subregion organized around a lumen, are not susceptible to low oxygen exposure [47].
Another key aspect in this research is related to the role of the unfolded protein response (UPR)
pathway in modulating cellular response to hypoxia. During phases of cellular stress such as in case of
oxygen deprivation, the UPR pathway aims to restore protein homeostasis [68,76]. TBR2+ intermediate
progenitors, which reside in a hypoxic environment, show an impaired activation of UPR, particularly
of the PERK–eIF2α–ATF4 pathway, and present an early neuronal differentiation. Human cortical
spheroids exposed to a small molecule known as integrated stress response inhibitor (ISRIB), which
restores protein translation in case of low PO2, present a higher density of TBR2+ cells and limit the
premature differentiation of the TBR2+ progenitors [47]. These results suggest that modulators of the
UPR pathways such as ISRIB might be useful to improve hypoxia-related defects in specific cortical
TBR2+ cell subpopulations. Moreover, although it remains to be determined how changes in specific
progenitors affect brain development, this study suggests that cortical organoids could be used as
models to evaluate cell susceptibility to hypoxia in fetal brains. Thus, 3D brain organoids can give
valuable insights into investigating new potential therapeutics and the effect of environmental factors
on brain development.
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4. 3D Models of Host-Pathogen Interactions
Cells terminally differentiated from iPSCs are susceptible to infections with human pathogens,
offering opportunities to investigate host-pathogen interactions. Human iPSCs models overcome the
limitations of species-specificity of infectious pathogens and inflammatory responses, with a resulting
translational potential [77,78]. IPSCs-derived neural organoids model virus-host interaction in the
context of Zika virus (ZIKV) and Herpesviruses
4.1. Zika Virus
ZIKV has been linked to serious neurological diseases, including Guillain-Barre syndrome and
to congenital malformations, such as microcephaly [79]. Despite clinical evidence, there had been
no direct experimental proof showing that ZIKV is able to cause early brain defects until 2016 [80].
Since then, several studies have shown the importance of 3D cultures in elucidating the mechanisms of
ZIKV infection. Three landmark publications in the field illustrate that ZIKV disrupts the generation of
neurospheres, induces neural precursor cell death and reduces the overall growth of organoids [29,81,82]
(Figure 2). Particularly, ZIKV exhibits a specific trophism towards SOX2+ neural precursor cells and
induces a decrease in neuronal cell-layer volume, resembling microcephaly [29]. Recently, ZIKV has
been shown to cause microcephaly as well as a lissencephaly-like phenotype in a human 3D model of
cortical folding [83].
IPSCs-derived brain organoids have helped to unravel some of the underlying mechanisms
of virus-induced microcephaly in humans. Impaired recruitment of centrosome proteins has been
reported as a key mechanism in genetic induced microcephaly [84,85]. Similarly, ZIKV perturbs
centrosome function, promoting incorrect orientation of the mitotic plane, leading to neural progenitor
cells depletion as reported in a study using human neurospheres [86]. AXL protein is considered an
important virus entry-receptor in NPCs as shown both in 2D- and 3D-based studies [21,87]. However,
ZIKV infection in cerebral organoids is not affected by AXL ablation [88]. Accordingly, early treatment
of forebrain organoids with inhibitors of AXL such as small molecules (R428) or blocking antibodies
leads to limited effects on virus-induced disruption in neurogenesis [63].
Human neural organoids have proved to model ZIKV replication and disruption of neurogenesis
underlying virus-mediated microcephaly, thus they are being used for testing potential drugs. Several
compounds have been screened in 2D NPCs cultures, and emricasan, a pan-caspase inhibitor, has
been the most effective suppressor of ZIKV-mediated caspase activity in vitro [89]. Though not
inhibiting ZIKV replication, emricasan neuroprotective effect has been confirmed when tested on brain
organoids [89]. In a different study, hiPSCs differentiated into NPCs have been exposed to ZIKV and
screened for potential drugs blocking ZIKV infection [90]. Hippeastrine hydrobromide (HH) and
amodiaquine dihydrochloride dihydrate present the highest efficacy. Forebrain organoids have been
used to validate the ability of these two selected drug candidates with anti-ZIKV activity to rescue
microcephaly-related defects [90]. Particularly, HH induces a decrease of progenitor proliferation,
ZIKV-induced apoptosis and suppresses ZIKV copies to undetectable levels. In addition, ZIKV
activates anti-viral immunity by triggering the production of small interfering RNA in hNPCs [91].
Accordingly, enoxacin, a broad-spectrum antibiotic working as an RNA interfering enhancer, exerts
a strong anti-ZIKV effect, preventing infection and microcephaly-like phenotype in human brain
organoids [91].
4.2. Herpesviruses
Herpesviridae family is a heterogeneous group of viruses with a tropism for critical organs such
as hematological and vascular system, gastrointestinal tract and the nervous system and may cause
severe complications in apparently healthy individuals. The outcome of herpesvirus infection can
be dramatic when they reach some anatomical regions such as the CNS or in immunocompromised
subjects, aged patients and newborns. Herpes simplex virus (HSV) and Cytomegalovirus (CMV)
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are two important herpesviruses leading to congenital infections and intrauterine growth restriction.
Symptomatic infants at birth show different neurological disorders including mental retardation, vision
loss, hearing impairment and microcephaly [92]. In addition, herpesvirus infections in neonates are
associated with encephalitis and high mortality, despite early antiviral treatment [93]. Precise reasons
for the increased severity of disease in newborns remain obscure [94]. Particularly, a poorly understood
process in herpesvirus infection is the role of cell susceptibility and viral latency, involving close
interactions between the virus and its host cell [95].
Cerebral organoids derived from iPSCs have been used to model CMV and HSV infections
in vitro. Organoid cultures derived from CMV-infected iPSCs include the viral genomes and show
decreased cellularity, cysts, vacuoles and areas of necrosis. B-tubulin III, a post-mitotic marker of neural
differentiation localized in the axon, presents an aberrant expression associated with a disruption of
neural projections and lamination within the cortical layers of the organoids [40]. These results parallel
observations in infected human clinical samples, reporting delayed neural maturation and abnormal
cortical lamination [96,97], proving the valuable role of 3D cultures in modeling some aspects of
CMV-induced pathology in developmental brain. Similarly, brain organoids have been used to evaluate
HSV-1 latency and reactivation in vitro. 3D cultures can be efficiently infected with HSV-1, showing the
susceptibility of MAP2-positive neurons to the lytic phase of infection [98]. Interestingly, the efficient
chemically induced reactivation of HSV-1 latent phase in 2D cultures is limited in 3D systems. These
results are consistent with the findings in animal models, which suggest a difficult HSV-1 reactivation
in CNS (differently from peripheral ganglia) [98,99]. These studies show the value of organoid systems
in recapitulating some aspects of host-pathogen interaction in human herpesvirus infections.
Collectively, these studies demonstrate that human iPSC-derived cultures can reproduce
host–pathogen interactions across different infections. Although 3D cultures at this stage are not a
replacement of in vivo models to study the role of adaptive immunity or the systemic manifestations
of infectious diseases, they represent a valuable platform, potentially enabling disease modeling and
screening of new therapeutics. We expect that improvement of organoid systems, particularly by the
differentiation of immune and inflammatory cells within their architecture, will expand the variety of
3D-based infectious disease models. We posit that the current limits of translating the findings from
animal models into therapies due to species-specificity of host-pathogen interactions will promote
iPSCs-based models in infectious disease research.
5. Models of Brain Cancer
Glioblastoma multiforme (GBM) is the most lethal primary brain tumor in adults. With a 5-year
survival rate of less than 5% [100] median survival rates have almost not changed in the last 30 years.
Chemo- and radiotherapy combined with brain surgery still remain the main therapeutic options,
though associated with low clinical response and important side effects [101].
Genetically engineered mice, tumor spheroids and patient-derived xenograft models have
improved our understanding of brain tumorigenesis [102]. However, limited donor availability, cancer
progression away from human genetic and epigenetic signatures [103], poor clinical translatability and
genetic heterogeneity of donor patients have prompted the search for additional models [104]
Such as 3D cultures. Organoid cultures reproduce complex three-dimensional features and
tumor host-cell interactions that may resemble brain cancer microenvironment, not recapitulated in
standard 2D conditions [105]. Tumor microenvironment greatly influences cancer cell proliferation
and incorporates several cellular lineages including macrophages, endothelia, pericytes, and
fibroblasts [106], not fully present in neural organoids at this stage. Nonetheless, human brain
organoids have already proved their validity in investigating tumor growth in cancer chimeric models
and genetic alterations that underlie the putative initial genetic events of tumorigenesis [107]. Indeed,
different researches involve iPSC-, ESC- and cancer stem cell-derived brain organoids generated to
model brain glioblastoma and develop high throughput drug screening platforms.
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In a study by Hubert et al., neural organoids derived from different regions of patients’ GBM
samples have been differentiated to recapitulate features of tumor microenvironment using a
modification of Lancaster’s protocol [108]. These organoids show different grades of tumor cell
infiltration consistent with the patient distinct tumor subregions of origin, maintaining functionally
diverse cancer cell populations within organoids’ architecture. In addition, GBM organoids display
regional heterogeneity with an outer area of rapidly dividing cells and a hypoxic core of both
differentiated senescent cells and dormant glioma stem cells (GSCs). Radiation therapy on tumor
organoids reveals heterogenous tumor radiosensitivity with sensitive differentiated GBM cells and
radioresistant GSCs, similarly to results in vivo [108,109]. Thus, cancer stem cell-derived organoids
recapitulate aspects of glioma heterogeneity and tumorigenic microenvironment in vitro.
Glioblastoma tumorigenesis has been investigated also in chimeric models exploiting CRISPR-cas9
technology combined with ESC-derived cerebral organoids [110] Particularly, glioblastoma within
neural organoids can be generated by simultaneously disrupting TP53 tumor suppressor and expressing
oncogenic HRasG12V in a small number of cells. These organoid-derived cancer cells, when
transplanted into the hippocampi of immunodeficient mice, exhibit tumoral molecular signatures and
tumorigenic properties such as rapid progression and invasiveness within murine brains, increasing
rodents’ mortality. In addition, these organoid-derived tumor cells can invade blood vessels and
strongly induce angiogenesis. In this case, neural chimeric models help to elucidate some early
genetic events of tumorigenesis and the tumor initiation of human gliomas, normally not investigable
in humans.
In another study, human neural organoids from iPSCs and ESCs co-cultured with different
patient-derived GSCs lineages display variable degrees of tumor invasiveness, consistent with GSC
line-specific behavior in vivo as seen in autopsy and surgical samples [105]. Moreover, tumor
brain organoids present abundant necrosis, mirroring human glioma histology [111] and a rich
microtube network [105], providing potential routes for tumor propagation in vitro and resembling
glioma growth in vivo [112]. Considering chemio- and radiosensitivity differences between GBM
organoids and 2D GSC-cultures, the organoid group shows high resistance to chemotherapy and
radiation-induced genotoxicity compared with 2D cultures, as seen often in vivo, suggesting a role of
3D microenvironment in drug resistance [105] (Figure 2). Brain tumorigenesis and chemotherapeutic
drug screening have been investigated also in an iPSCs-based neural organoid model of primitive
neuroectodermal tumor (CNS-PNET)-like neoplasm and GBM [50]. Particularly, by combining genome
editing techniques (CRISPR-cas9 and Sleeping Beauty transposon system), tumors have been generated
with the introduction of genetic aberrations in a small fraction of cells within the organoid, mimicking
tumor initiation in humans. Organoids overexpressing MYC show a transcriptional and histological
phenotype resembling CNS-PNET; these CNS-PNET organoid-derived cells show a distinctive genetic
signature compared with organoids presenting a combination of overexpressed and knockout genes
relevant for GBM. Indeed, by evaluating expression levels of invasion-related genes in tumor cells from
CNS-PNET and GBM organoids, the glioma group expresses more genes involved in invasiveness,
correlating with the lower infiltration propensity of neuroectodermal neoplasms in contrast to
high-grade gliomas in vivo [113]. To demonstrate the value of this system in chemotherapeutic drug
screening, tumor organoids have been treated with epithelial growth factor receptor (EGFR)-inhibitors,
which reduce tumor growth only in GBM organoids overexpressing EGFR [50].
Collectively, these studies highlight the validity of 3D cultures in recapitulating the initiating
events in brain cancer tumorigenesis, elucidating some aspects of tumor host-cell interactions as well
as the utility of neural organoids in drug testing.
6. New Frontiers in Neural Organoid Research: Human-Animal Chimeras
The development of 3D-based technologies has provided advancements in terms of maturation,
cellular complexity and diversity of neural models. However, the spatial confinement of organoid-based
disease models to tissue cultures has limited the study of their interactions with the immune, circulatory
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and endocrine system as well as the intricate molecular network present in vivo [114]. Moreover,
compared to neural stem cell niches in vivo, organoids lack afferentation structures and tend to
self-organize in vitro, missing both sensory signals conveyed through the host neural system and
important morphogenetic cues [110]. Lately, xenotransplantation of human iPSC-derived cells and
organoids into animal models have addressed these restrictions. Particularly, human cells from iPSCs
have been engrafted into immunocompromised mice to generate “humanized” chimeric models.
Human-rodent models based on iPSCs have proved to be valuable tools faithfully recapitulating
aspects of human disease in different organs by generating liver [115], solid tumors [116], pancreas [117],
lung [118], haemopoietic [119], retinal [120] and neural chimeras [107,121].
Here, we focus on the description of neural chimeras generated by in vivo transplantation of
iPSC-derived neural cells and organoids into animal models and their potential use in disease modeling.
Neural Chimeras
Engraftment of human neural tissue into animal models has been used for decades to study human
diseases [122]. The development of iPSC-based technologies, in addition to the propensity of human
iPSC cultures to differentiate towards neural tissue and to engraft organs, offered the opportunity for
new stem cell-based therapies [39,123]. Neurons derived from iPSCs form axonal projections with
functional synapsis connectivity and integrate within the host neural circuitry when xenografted into
the developing mouse brain [40]. In the last few years, different studies have shown the potential
use of iPSC-based therapies in neurological diseases. For instance, both human and non-human
dopaminergic neurons from iPSCs engraft in rat brains, improving functional performance in a model
of Parkinson disease (PD) [124]. Moreover, human iPSC-derived dopaminergic neurons autologously
transplanted into primates show long-term neuronal survival in vivo [124]. This solid evidence has
provided compelling preclinical basis for a currently ongoing human clinical testing with iPSC-derived
dopaminergic precursors in PD patients [10]. In a chimeric model of ischemic stroke, transplanted
neural stem cells from iPSCs differentiate into astrocytes and neurons, restoring part of the impaired
neurological function [125].
Lately, xenotransplantation of human 3D organoids has been characterized in murine models.
Organoid-like structures can self-organize within developing mouse cortex after engraftment of
iPSC-derived neural stem cells grown in a three-dimensional artificial extracellular matrix [126].
These data have been further expanded by successful transplantation of neural organoids into rodent
brains showing enhanced survival, multilineage differentiation and vascularization if compared with
transplantation of neural precursor cells [127]. In a recent study, intracerebral xenotransplantation of
human iPSC-derived brain organoids has been characterized in nonobese diabetic-severe combined
immunodeficient mice [128]. Neural organoids show successful engraftment within the murine cortex
demonstrating a robust vascularization from host brain. Moreover, in long-term analysis up to 9
months, transplanted organoids display progressive neuronal maturation and differentiation, the
formation of long-range axon projections and a host-graft functional neural network responsive to
physiological stimuli [128]. Although it’s still debatable whether neural organoids can restore specific
damaged or degenerated regions, the possibility of obtaining functional neural circuits between graft
and host cells provide an alternative for modeling complex neurological disorders in vivo.
An important study illustrates the use of neural chimeras to model neuropsychiatric diseases,
particularly Down syndrome (DS). IPSC-derived ventral forebrain organoids generated from
Down syndrome patients show an increased production of OLIG2neural precursor cells; these
cells transcriptionally drive neuronal differentiation towards GABAergic-interneurons [115], whose
imbalance probably play a role in cognitive symptoms in DS in humans [104]. Accordingly, chimeric
rodents xenografted with human DS organoids show an overabundance of GABAergic-interneurons
and impaired performance in memory tests; both phenotypes can be reversed by inhibiting OLIG2
expression [115]. In this case, the development of human-rodent chimeras helps to investigate the
interplay between abnormal gene expression and human interneuron development in vivo, offering
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new insights into disease pathogenesis of DS and into the modulation of specific genetic targets (OLIG2)
for a potential fetal therapy for Down syndrome.
Altogether, these studies highlight the feasibility of transplanting iPSC-derived cells and
organoids into chimeric mice, the advantages in terms of vascularization, cell maturation and neural
network development within engrafted organoids as well as the potential use of neural chimeras in
disease modeling.
7. Conclusions
We have provided an overview on the recent advances in modelling neurological disorders with
the use of iPSC derived neural organoids. Despite striking achievements, neural organoid systems still
present important limitations (Table 2).
Table 2. Pros and cons of neural organoids and potential solutions/current approaches to the major
limitations of the organoid model.
PROS CONS APPROACH
3D multicellular architecture with
complex cell
compartmentalization
Lack of reproducibility
- Microfluidic technologies modulating
local stimuli to
cellular microenvironment
- Patterned organoids
Patterning into different brain-like
subregions Cost
- Miniaturized spinning bioreactors
with reduced incubator space and
medium supply needed
Rough organization into cortical
layers
Lack of output and input
systems
- In vivo transplantation
- Development of assembloids
Long term culturing Lack of vascular bed
- Combined progenitors (mesenchymal
and neural stem cells)
- In vivo transplantation into
animal models
Generation of patients’specific
disease-relevant cell types Spatial orientation
- Bioengineered scaffolds
Generation of spontaneously
active neural networks Long term maturation
- In vivo transplantation
- Optimization of culture conditions
and culture media
For example, the derivation of different and reproducible brain regions within the organoid is still
a challenge. Multiple protocols are being developed to overcome this issue and tackle heterogeneity;
some of these are based on specific neural patterning through the use of small molecules that direct
the cells towards a specific fate such as midbrain, spinal cord and hippocampus [29,30,32]. Other
technologies have been optimized to ensure the intake of trophic factors into the organoid core through
the use of microfluidic technologies [129]
Moreover, organoids generated with available protocols don’t grow beyond the equivalent of a
early prenatal stage, which could represent a limitation for modelling diseases that onset after birth or
during adulthood. Indeed, the lack of vascularization in the neural tissue hinders long-term maturation
of neural organoids. In vivo transplantation of human neural organoids into adult murine brains [128]
or organ buds generated by combining specific neural progenitors with mesenchymal stem cells [130]
represent valuable solutions.
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Brain organoids are deprived of structures that provide spatial orientation during development.
The advancement of bioengineering techniques offers interesting perspectives for the production
of specific scaffolds [131] able to support and guide the growing tissue and that can be selectively
permeated by gradients of small molecules.
In addition, methods to maximize the variety of cell populations within the organoid have
been recently published focusing on the development of microglia [132] and oligodendrocytes [133].
The deficiency of inputs from the sensory system can be partially overcome by generating interconnected
assembloids [134] or transplanting organoids within a host neural circuit [126]. This strategy ensures a
proper amount of blood flood and synaptic inputs to the graft, which can be studied in its interaction
with the host environment.
Although organoids are in principle amenable to high-throughput screenings, current methods
require technical efforts and important manipulations that have hindered progress. Researchers
have used organoids modelling epithelial cancers [135,136] and kidney [137] for drug discovery with
high-throughput approaches, but well-established and validated methods exploiting neural organoids
still lack. Recently, Qian et al. have optimized existing protocols to generate neural organoids as
potential platforms for drug discovery [29]. A key advancement in organoid technology has been the
use of spinning bioreactors to enable nutrient and oxygen diffusion, increasing the size and complexity
of organoids [46]. Unfortunately, most of available spinning bioreactors require a consistent supply
of medium over months of culturing and much incubator space, increasing the cost. These obstacles
preclude scalability and compound screening in many laboratories, and they limit the possibility of
testing different conditions to optimize protocols. Qian et al. have used a low-cost, miniaturized
spinning bioreactor system to generate hypothalamic, midbrain and forebrain organoids by exposition
to different patterning factors [29]. Forebrain organoids differentiated with this system have been
exposed to ZIKV at various developmental stages. Infection of neural progenitor cells in early phases
directly correlates with reduced organoid size, decreased neuronal thickness and dilated ventricles as
demonstrated in previous researches using different bioreactors [29,90]. This system could serve as
low cost and effective platform for drug discovery using neural organoids.
Despite these limitations, neural organoids have already provided valuable insights into
neurological disorders offering a platform to investigate cellular interactions and circuit dysfunction.
The possibility to genetically manipulate organoids have allowed to study the pathogenetic effect of
disease causative mutations and test potential therapeutic compounds.
Altogether, these results suggest that the creation of refined and complex brain organoids will
allow a deeper investigation of human neural development and pathology. Moreover, they can be
a precious tool to study patients’ specific mutations and epigenetic profile with the ultimate aim to
design personalized therapeutic strategies. Further researches will be needed to optimize and refine
3D system models for extensive translational application.
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